Participated · Equity · Jun 2025

myLaurel has built a technology-enabled, hospital-aligned model for acute and transitional care at home, combining AI-driven logistics orchestration with virtual physician oversight and hands-on clinical teams. Operating in markets such as New York City and New Orleans, the company partners with health systems including Ochsner Health, LCMC Health, and Maimonides Medical Center to alleviate emergency-department crowding and workforce shortages. Its platform reports a 49 percent reduction in readmissions, a 6-to-1 return on investment for hospital partners, and patient satisfaction scores above 90 NPS, illustrating strong clinical and financial outcomes. The new capital will fund a nationwide rollout, expanding partnerships with major U.S. health systems and scaling its AI infrastructure. Led by CEO Juan Vallarino and President & Chief Medical Officer Dr. Marcy Carty, the team brings deep experience in value-based and technology-enabled care models. Future plans center on rapid geographic expansion while maintaining high standards of clinical quality and patient experience. No revenue or user counts were disclosed in the articles.

Participated · Series B · Jul 2024

Clarapath develops robotics, machine vision and digital automation tools to modernize how pathology laboratories process tissue, with its SectionStar system positioned as an all‑in‑one tissue sectioning and transfer solution. SectionStar is described as the first (pending U.S. launch) system that increases capacity, reliability and consistency while reducing the need for highly skilled labor. The company says its automation captures and aggregates new data to improve downstream digital pathology and diagnostic review. Clarapath cites a strained laboratory environment driven by severe labor shortages, rising caseloads and antiquated manual workflows as rationale for its products; the article notes more than 12 million human and veterinary biopsies are performed annually in the U.S. The company operates medical device development in Hawthorne, NY and runs a CLIA‑certified laboratory serving clinical and non‑clinical organizations. With this financing, Clarapath plans to accelerate commercialization of SectionStar and expand sales, service, precision manufacturing and R&D to build an end‑to‑end 'lab of the future.' Clarapath develops SectionStar, a fully automated, all‑in‑one tissue sectioning and transfer system that standardizes and accelerates the preparation of glass slides for pathology. SectionStar consolidates manual cutting, quality control, and decision steps to produce more consistent tissue sections and support AI‑driven analysis. The company says the system increases throughput, reduces reliance on skilled labor, and generates richer datasets for molecular mapping and precision‑medicine research. Clarapath works with research and clinical customers today, including Northwell Health and The Ellison Institute, and operates a CLIA‑certified clinical research organization that offers whole slide imaging and automated image processing. The company plans to launch SectionStar first in the non‑clinical market in the near term while targeting the larger clinical market as its ultimate goal. Recent financing will support product development, team growth, and expanded sales and service efforts.

Participated · Seed · Mar 2024

Nest Health delivers integrated medical, behavioral, and social care to entire households, replacing the fragmented experience of juggling pediatric, adult, and mental-health providers. Families receive age- and stage-aligned in-home visits augmented by virtual consultations, 24/7 clinical support, and coordinated referrals to specialists. The company’s offering spans primary care, mental-health and substance-use treatment, and social-needs assistance such as housing or utilities support. Its AI tools automate workflows before, during, and after caregiver interactions to boost care-team efficiency. Founded by Dr. Rebekah Gee, Nest Health currently operates in Louisiana and Arizona and targets Medicaid populations. The fresh $22.5 million Series A financing strengthens its balance sheet and will fund expansion of its AI-driven clinical products and geographic footprint through new and existing payer partnerships.

Participated · Equity · Oct 2023

Capital Rx operates a cloud-native pharmacy benefit management (PBM) platform that adjudicates prescription drug claims and provides price transparency to employers, insurers, and other payers. The company is now broadening its technology to handle medical claims as well, positioning itself as an end-to-end claims processor across both pharmacy and medical benefits. By unifying these workflows, Capital Rx aims to give payers better visibility into total healthcare spending and negotiate more favorable rates. Management says the fresh capital will accelerate product expansion and support additional hiring to meet customer demand. The firm reports an oversubscribed funding round and cites strong interest from new and existing investors. A spokesperson disclosed that Capital Rx now carries a $3.25 billion valuation, underscoring investor confidence in its growth trajectory. Although detailed revenue or user metrics were not provided, the company emphasized that the additional funds will enable it to scale its platform nationwide.